Like us on Facebook

ASH news: Eduardo Olavarria presented findings from a study done by the European Society for Bone and Marrow Transplantation, which showed that there was no difference in outcomes between patients who took either Dasatinib or Nilotinib, or a combination. ...

View on Facebook

Dr. Dennis Kim from Toronto's Princess Margaret Cancer Centre: Treatment-free success is largely determined by how long you have maintained a response of MR 4.5 or better. ...

View on Facebook

Follow Us on Twitter

Latest Tweets


Photo Credits:


Angel Acevedo/

Will Langenberg/